BioAsia 2009 in Tokyo: alliance opportunities exist but right approach needed
This article was originally published in Scrip
Executive Summary
With the environment for IPOs set to remain challenging to non-existent for the remainder of this year, and venture capital having shrivelled up alarmingly, pharma and biotech ventures could be forgiven for feeling depressed about their prospects.